New drug cocktail aims to deeply suppress blood cancer
NCT ID NCT07582159
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This study tests a combination of three drugs (acalabrutinib, venetoclax, and tafasitamab) in 35 adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if the combo is safe and can achieve a complete response with undetectable cancer cells. Participants will take all three drugs for a set period, and the study will monitor side effects and treatment success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.